Navigation Links
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Date:10/31/2007

Transaction Expands King's Near-term Pipeline of Products Designed to Deter

Common Methods of Opioid Abuse

BRISTOL, Tenn. and PALATINE, Ill., Oct. 31 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (OTC Bulletin Board: ACUR) announced today that the companies have entered into a License, Development and Commercialization Agreement (the "Agreement") for the United States, Canada, and Mexico (the "Territory") encompassing a potentially wide range of opioid analgesic products utilizing Acura's patented Aversion(R) (abuse-deterrent) Technology platform. The companies have initially targeted development and commercialization of four immediate release opioid analgesic products, including ACUROX(TM) Tablets (oxycodone HCl, niacin, and a unique combination of other ingredients), formerly known as OxyADF, for treating moderate to severe acute pain.

Brian A. Markison, Chairman, President and CEO of King, stated, "This transaction demonstrates our commitment to building on our strengths in specialty markets where we have a strong presence and existing capabilities. We are excited about partnering with Acura, which directly aligns with our recently announced emphasis on King's neuroscience and hospital/acute care platforms, particularly our growing pain management franchise."

Andy Reddick, President and CEO of Acura said, "We believe King's abuse- deterrent analgesic brand product pipeline and neuroscience expertise perfectly complement our Aversion(R) Technology platform. King is clearly leading the pharmaceutical industry with its understanding of the opportunities and challenges relating to the market for products designed to discourage presc
'/>"/>

SOURCE King Pharmaceuticals, Inc.; Acura Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... proportion of patients with advanced cancer and a life ... common cancer screening tests that are unlikely to provide ... 13 issue of JAMA . Cancer ... (PSA) and colonoscopy, evaluate asymptomatic patients for the detection ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay ... transfusions do just as well as those who receive more, ... varies widely among U.S. hospitals. The studies are published ... the American Medical Association . In the first study, ...
... GABLES, FL (October 12, 2010)--Still hampered by workforce shortages ... care to the full extent of their education and ... the arm they need to transform their profession with ... recommending sweeping changes for improving their profession. The report, ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Oct. ... cancer care has long been known by researchers, with ... cancer treatments than white patients. "Less well known is ... something else contributing?" said Dr. Rachel Freedman, a medical ...
... of a large Phase-III clinical trial have shown that ... a hard-to-treat group of rare cancers that affect particular ... European Society for Medical Oncology (ESMO), Dr Marianne Pavel ... improved progression-free survival by 5.1 months in patients with ...
... population ages, health care epidemiologist Padma Kaul and cardiologist Paul ... the University of Alberta, want health-care professionals to talk to ... it be at home, in hospital or a palliative care ... recent study, that the majority of heart failure patients pass ...
Cached Medicine News:Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 2Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 3Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:National committee releases findings on transforming and improving the nursing profession 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2Health News:Medical researchers break down costs to care for heart failure patients at the end of life 2
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
The CE marked HF coagulator which meets the highest ISO safety features....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: